The following is an archived copy of a message sent to a Discussion List run by the Campaign Against Sanctions on Iraq.
Views expressed in this archived message are those of the author, not of the Campaign Against Sanctions on Iraq.
[Main archive index/search] [List information] [Campaign Against Sanctions on Iraq Homepage]
Hi Mark, The discussion of irregular arrivals of leukaemia drugs that I remember was in the John Pilger / Felicity Arbuthnot documentary. In that, Pilger interviewed Prof. Karol Sikora, an oncologist in London. Sikora stresses the importance of carefully staged treatments, and the impossibility of maintaining them in Iraq. If you're interested in researching this further, I would recommend speaking to Sikora. The second people to speak to would be the people at the Office of the Iraq Programme in New York. In particular, Hasmik Egian is the information officer, and it's her job to answer questions like this. She can be phoned in New York on +1 212 963 4341. >From the point of view of imports, the most interesting question to me is how many of the leukaemia drugs are NOT on the 'green lists' (Hasmik could probably help with this). Drugs that are on the green lists can be imported without the Sanctions Committee's approval. If the arrival of 'green list' drugs is slow, it suggests that other factors are delaying them. These could include the supplier's reliability, which might be chosen for political as well as commercial factors. Proper treatment for leukaemia depends on much more, of course, than mere availability of drugs. Nurses and doctors must be capable of providing treatment, and must be available. This requires payment of their salaries, and a budget for their training, both of which have been impeded by sanctions. Hospitals need to be well-equipped, clean and have electricity; these too require a well-functioning system that sanctions have harmed. I hope that this helps, Colin Rowat work | Room 406, Department of Economics | The University of Birmingham | Birmingham, B15 2TT, UK | web.bham.ac.uk/c.rowat | (+44/0) 121 414 3754 | (+44/0) 121 414 7377 (fax) | firstname.lastname@example.org personal | (+44/0) 7768 056 984 (mobile) | (+44/0) 7092 378 517 (fax) | (707) 221 3672 (US fax) | email@example.com -----Original Message----- From: firstname.lastname@example.org [mailto:email@example.com]On Behalf Of Mark Al-Sinjakli Sent: Thursday, February 21, 2002 9:25 AM To: firstname.lastname@example.org Subject: Child Leukaemia Treatment in Iraq Dear All I'm writing to you on a point of information I'm trying to clarify. I'm sure I read somewhere that the drugs used to treat leukaemia arrive in drips and drabs because of the process of applying for a license. I know that they are needed all at once, but another key factor for me is the shelf-life of the drugs: does anyone know if they have a limited shelf-life? I've tried all kinds of searches on CASI's archive but have been unable to source the specific reference. Thanks for your help Mark Mark Sinjakli email: email@example.com firstname.lastname@example.org Do You Yahoo!? Get personalised at My Yahoo!. _________________________________________________________ Do You Yahoo!? Get your free @yahoo.com address at http://mail.yahoo.com -- ----------------------------------------------------------------------- This is a discussion list run by the Campaign Against Sanctions on Iraq For removal from list, email email@example.com CASI's website - www.casi.org.uk - includes an archive of all postings.